NeoGenomics Signs Definitive Agreement to Acquire Genoptix

NeoGenomics has reached an agreement to acquire Genoptix.

Both NeoGenomics and Genoptix have a longstanding and strong commitment to meeting the unique diagnostic laboratory testing needs of hospitals, pathologists, and oncologists. We believe the combined company will provide many benefits for customers of both organizations.

NeoGenomics’ industry-leading molecular services and broad oncology test menu is highly complementary with Genoptix’s innovative services and reporting solutions focused on hematologic cancers. In combining the two companies, our goal is to achieve the highest level of quality testing and exceptional service by leveraging each company’s best practices with the aim of providing exceptional service to our clients and improving the care of patients with cancer.  We believe we will be uniquely positioned to help coordinate care with pathologists and oncologists in the local community.

Until the transaction closes, which is expected by year end, NeoGenomics and Genoptix must continue to operate as separate companies. During this planning period and the subsequent integration, we will proactively keep you informed, but please do not hesitate to contact us with questions.

See full press release.

Source: Neogenomics